

## INFORME DE BÚSQUEDA DE PATENTES

**N° de solicitud:** NC2017/0001626

**CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados\*. Para el caso de secuencias, anexar alineamientos)**

|                                                    |                                                                                                                                                          |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>PALABRAS CLAVE UTILIZADAS</b>                   | Anti-orai1 OR IMD9 OR TAM2 OR ORAT1 OR CRACM1 OR TMEM142A                                                                                                |
| <b>CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA</b> | <b>CIP:</b> C12N 15/09, A61K 39/395, A61P 7/00, A61P 29/00, A61P 35/00, A61P 37/00, C07K 16/18, C07K 16/46, C12N 1/15, C12N 1/21, C12N 5/10, C12P 21/08. |

### DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)

| Informes/Base de datos                     | N° de solicitud/ Autor** | Fecha de Publicación/ Presentación (DD/MM/AAAA) | Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias) | Categorías especiales de los documentos citados*** |
|--------------------------------------------|--------------------------|-------------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------|
| SIPI                                       | NA                       |                                                 |                                                                                                |                                                    |
| ISA(EPO)                                   | Cox et al.               | 23/12/2013                                      | NA                                                                                             | A                                                  |
| ISA(EPO)<br>EPO                            | wo2011/063277            | 26/05/2011                                      | NA                                                                                             | A                                                  |
|                                            | wo2013/091903            | 27/06/2013                                      | NA                                                                                             | A                                                  |
|                                            | Lin et al.               | 01/05/2013                                      | NA                                                                                             | A                                                  |
| NCBI (SEQ. 43, 56, 58, 60, 62, 64, 66, 70) | NA                       |                                                 |                                                                                                |                                                    |

\*\*\* Categorías especiales de documentos citados:

|                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>“A”</b> documento que define el estado general de la técnica no considerado como particularmente relevante.</p> <p><b>“E”</b> solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior.</p> <p><b>“P”</b> documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.</p> | <p><b>“X”</b> documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.</p> <p><b>“Y”</b> documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.</p> |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

\*\*\*\* Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.

|                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>Literatura no patente</b></p> <p>**Se incluye entre otros, toda la referencia de la literatura no patente.</p> | <p>Lin, F. F., Elliott, R., Colombero, A., Gaida, K., Kelley, L., Moksa, A., ... &amp; Hu, S. (2013). Generation and characterization of fully human monoclonal antibodies against human Orai1 for autoimmune disease. <i>Journal of Pharmacology and Experimental Therapeutics</i>, 345(2), 225-238.</p> <p>Cox JH, Hussell S, Søndergaard H, Roepstorff K, Bui J-V, Deer JR, et al. (2013) Antibody-Mediated Targeting of the Orai1 Calcium Channel Inhibits T Cell Function. <i>PLoS ONE</i> 8(12): e82944. <a href="https://doi.org/10.1371/journal.pone.0082944">https://doi.org/10.1371/journal.pone.0082944</a></p> |
|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                       |            |
|---------------------------------------|------------|
| <b>Fecha del reporte de búsqueda:</b> | 06/04/2018 |
|---------------------------------------|------------|

## UNIDAD DE INVENCION

### Cadenas ligeras

CLUSTAL multiple sequence alignment by MUSCLE (3.8)

```
56      MVLQTQVFISLLLWISGAYGDIQLTQSPSSLSASVGDRVTITCRASQSIGGSLSWFQQKP
58      MVLQTQVFISLLLWISGAYGDIQLTQSPSSLSASVGDRVTITCHASQNIGGSLSWFQQKP
60      MVLQTQVFISLLLWISGAYGDIQLTQSPSSLSASVGDRVTITCHASRNIGGSLSWFQQKP
          *****.**.*****

56      GKAPKRLIYSTSTLESQVPSRFSGSGSGTDYTLTISSLQPEDFAMYYCLQFAIFPDSFGQ
58      GKAPKRLIYLTSTLDWGVPSRFSGSGSGTDYTLTISSLQPEDFAMYYCLQFAIFPDSFGQ
60      GKAPKRLIYLTSSLDWGVPSRFSGSGSGTDYTLTISSLQPEDFAMYYCLQFAIFPDSFGQ
          ***** **: *****

56      GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
58      GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
60      GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
          *****

56      ESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
58      ESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
60      ESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
          *****
```

### Cadenas pesadas

CLUSTAL multiple sequence alignment by MUSCLE (3.8)

```
66      MKHLWFFLLLVAAPRWVLSQVQLVQSGAEVKKPGASVKVSCKASGYPI TAYYISWVRQAP
64      MKHLWFFLLLVAAPRWVLSQVQLVQSGAEVKKPGASVKVSCKASGYPI TAYYISWVRQAP
43      MKHLWFFLLLVAAPRWVLSQVQLVQSGAEVKKPGASVKVSCKASGYPVTAYYISWVRQAP
70      MKHLWFFLLLVAAPRWVLSQVQLVQSGAEVKKPGASVKVSCKASGYPVTAYYISWVRQAP
62      MKHLWFFLLLVAAPRWVLSQVQLVQSGAEVKKPGASVKVSCKASGYPVTAYYISWVRQAP
          *****:*****

66      GQGLEYYVGYIDMGNGRTDYNMRFKGRATLTVDKSTSTAYMELSSLRSED TAVYYCARD SN
64      GQGLEYYVGYIDMGNGRTDYNGRFKGRATLTVDKSTSTAYMELSSLRSED TAVYYCARD SN
43      GQGLEYYVGYIDMGNGRTNYNARFKGRATLTVDKSTSTAYMELSSLRSED TAVYYCARD SN
70      GQGLEYYVGYIDMGNGRTDYNARFKGRATLTVDKSTSTAYMELSSLRSED TAVYYCARD SN
62      GQGLEYYVGYIDMGNGRTDYNARFKGRATLTVDKSTSTAYMELSSLRSED TAVYYCARD SN
          *****: ** *****

66      WGADYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSG
64      WGADYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSG
43      WGV D YWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSG
70      WGADYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSG
62      WGADYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSG
          ** . *****
```

```

66     ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD
64     ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD
43     ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD
70     ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD
62     ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD
        *****

66     KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
64     KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
43     KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
70     KTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
62     KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
        *****

66     VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
64     VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
43     VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
70     VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
62     VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
        *****

66     QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
64     QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
43     QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
70     QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
62     QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
        *****

66     GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
64     GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
43     GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
70     GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
62     GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
        *****

```

|          |         |
|----------|---------|
| Buscador | Ncbi-nr |
| query    | Seq 56  |

|                          | Description                                                                                                                               | Max score | Total score | Query cover | E value | Ident | Accession              |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------------|-------------|---------|-------|------------------------|
| <input type="checkbox"/> | <a href="#">Chain L, Humanized 10g4 Anti-leukotriene C4 Antibody Fab Fragment In Complex With Leukotriene C4</a>                          | 403       | 403         | 91%         | 3e-141  | 92%   | <a href="#">5KVL_L</a> |
| <input type="checkbox"/> | <a href="#">Chain A, Crystal Structure Of Abt-007 Fab Fragment With The Soluble Domain Of Epo Receptor</a>                                | 402       | 402         | 91%         | 4e-141  | 91%   | <a href="#">2JIX_A</a> |
| <input type="checkbox"/> | <a href="#">Chain L, X-RAY STRUCTURES OF FRAGMENTS FROM BINDING AND NONBINDING VERSIONS OF A HUMANIZED AN</a>                             | 400       | 400         | 91%         | 4e-140  | 92%   | <a href="#">2FGW_L</a> |
| <input type="checkbox"/> | <a href="#">Chain B, Crystal structure of H7-specific antibody m826 in complex with the HA1 domain of hemagglutinin from H7N9 influen</a> | 399       | 399         | 91%         | 6e-140  | 91%   | <a href="#">5VAG_B</a> |
| <input type="checkbox"/> | <a href="#">Chain L, Structure Of Neutralizing Antibody Bound To Zika Envelope Protein</a>                                                | 399       | 399         | 91%         | 7e-140  | 90%   | <a href="#">5GZO_L</a> |
| <input type="checkbox"/> | <a href="#">Chain L, Crystal Structure Of Fab15 Mut8</a>                                                                                  | 399       | 399         | 91%         | 1e-139  | 91%   | <a href="#">3NCJ_L</a> |
| <input type="checkbox"/> | <a href="#">Chain L, The Structure Of The First Ywtd Beta Propeller Domain Of Lrp6 In Complex With A Fab</a>                              | 399       | 399         | 93%         | 2e-139  | 89%   | <a href="#">3SOB_L</a> |
| <input type="checkbox"/> | <a href="#">Chain D, Antibody Fab Fragment Complex</a>                                                                                    | 398       | 398         | 91%         | 2e-139  | 90%   | <a href="#">5JO4_D</a> |
| <input type="checkbox"/> | <a href="#">Chain L, Crystal Structure Of Certolizumab Fab</a>                                                                            | 397       | 397         | 91%         | 3e-139  | 90%   | <a href="#">5WUV_L</a> |
| <input type="checkbox"/> | <a href="#">Chain L, Crystal Structure Of Notch3 Nrr In Complex With 20350 Fab</a>                                                        | 397       | 397         | 91%         | 3e-139  | 90%   | <a href="#">5CZV_L</a> |
| <input type="checkbox"/> | <a href="#">Chain L, Crystal structure of Spinach RNA aptamer in complex with Fab BL3-6S97N</a>                                           | 397       | 397         | 91%         | 3e-139  | 90%   | <a href="#">6B14_L</a> |
| <input type="checkbox"/> | <a href="#">Chain B, Crystal Structure Of A Fab Binding To Extracellular Domain 5 Of Cadherin-6</a>                                       | 397       | 397         | 91%         | 3e-139  | 91%   | <a href="#">5VEB_B</a> |

|          |         |
|----------|---------|
| Buscador | Ncbi-nr |
| query    | Seq 56  |

|                          | Description                                                                                   | Max score | Total score | Query cover | E value | Ident | Accession                  |
|--------------------------|-----------------------------------------------------------------------------------------------|-----------|-------------|-------------|---------|-------|----------------------------|
| <input type="checkbox"/> | <a href="#">precursor of immunoglobulin heavy chain [synthetic construct]</a>                 | 832       | 832         | 100%        | 0.0     | 89%   | <a href="#">BAN81713.1</a> |
| <input type="checkbox"/> | <a href="#">IGHG1 [synthetic construct]</a>                                                   | 823       | 823         | 100%        | 0.0     | 90%   | <a href="#">AIC63043.1</a> |
| <input type="checkbox"/> | <a href="#">unnamed protein product [Homo sapiens]</a>                                        | 823       | 823         | 100%        | 0.0     | 89%   | <a href="#">BAG62928.1</a> |
| <input type="checkbox"/> | <a href="#">anti-rabies SO57 immunoglobulin heavy chain [Homo sapiens]</a>                    | 821       | 821         | 100%        | 0.0     | 89%   | <a href="#">AAO17821.1</a> |
| <input type="checkbox"/> | <a href="#">humanized murine anti-VEEV antibody Hy4-26C heavy chain [synthetic construct]</a> | 819       | 819         | 95%         | 0.0     | 92%   | <a href="#">ABH10632.1</a> |
| <input type="checkbox"/> | <a href="#">unnamed protein product [Homo sapiens]</a>                                        | 818       | 818         | 100%        | 0.0     | 89%   | <a href="#">BAG65283.1</a> |
| <input type="checkbox"/> | <a href="#">IGHG1 [synthetic construct]</a>                                                   | 817       | 817         | 100%        | 0.0     | 89%   | <a href="#">AIC63046.1</a> |
| <input type="checkbox"/> | <a href="#">unnamed protein product [Homo sapiens]</a>                                        | 810       | 810         | 100%        | 0.0     | 87%   | <a href="#">BAC85175.1</a> |
| <input type="checkbox"/> | <a href="#">IgG [Homo sapiens]</a>                                                            | 810       | 810         | 100%        | 0.0     | 88%   | <a href="#">AAA02914.1</a> |
| <input type="checkbox"/> | <a href="#">IGHM [synthetic construct]</a>                                                    | 810       | 810         | 100%        | 0.0     | 87%   | <a href="#">AIC63052.1</a> |
| <input type="checkbox"/> | <a href="#">chimeric anti-human type VII collagen immunoglobulin G1 [synthetic construct]</a> | 808       | 808         | 99%         | 0.0     | 88%   | <a href="#">ACN59874.1</a> |
| <input type="checkbox"/> | <a href="#">unnamed protein product [Homo sapiens]</a>                                        | 807       | 807         | 100%        | 0.0     | 87%   | <a href="#">BAC85199.1</a> |

|             |                                                      |
|-------------|------------------------------------------------------|
| Buscador    | Ncbi-PATENTED SEQUENCES                              |
| query       | Seq 43, 56, 58, 60, 62, 64, 66, 70                   |
| ENTREZ TERM | orai1 OR IMD9 OR TAM2 OR ORAT1 OR CRACM1 OR TMEM142A |

## BLAST » blastp suite » RID-CGGPTSJ6014

**BLAST Results** [Home](#) [Recent Results](#) [Saved Strategies](#) [Help](#)

Your search is limited to records that include:  
 entrez query: **orai1 OR IMD9 OR TAM2 OR ORAT1 OR CRACM1 OR TMEM142A** [Full Entrez Query](#)

[Edit and Resubmit](#) [Save Search Strategies](#) [Formatting options](#) [Download](#) [YouTube](#) [How to read this page](#)

**Job title: 8 sequences (56)**

|                      |                                |
|----------------------|--------------------------------|
| <b>Results for:</b>  | *1: cl Query_79126 56(234aa) ▼ |
| <b>RID</b>           | *1: cl Query_79126 56(234aa)   |
| <b>Query ID</b>      | *2: cl Query_79127 58(234aa)   |
| <b>Description</b>   | *3: cl Query_79128 60(234aa)   |
| <b>Molecule type</b> | *4: cl Query_79129 43(466aa)   |
| <b>Query Length</b>  | *5: cl Query_79130 62(466aa)   |
|                      | *6: cl Query_79131 64(464aa)   |
|                      | *7: cl Query_79132 66(466aa)   |
|                      | *8: cl Query_79133 70(466aa)   |

-08 12:02 pm)

**Database Name** pat  
**Description** Protein sequences derived GenBank  
**Program** BLASTP 2.8.0+ [Citation](#)

**No significant similarity found. For reasons why, [click here](#)**

[Questions/comments](#)

|          |                   |
|----------|-------------------|
| Buscador | LENS- FINDER      |
| query    | Seq 62            |
| FILTER   | BEFORE 07/08/2014 |

| Patent Number                      | Title                                                                                            | Publication Date | SEQ ID NO           | Local % Id |
|------------------------------------|--------------------------------------------------------------------------------------------------|------------------|---------------------|------------|
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">96</a>  | 94.4%      |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">75</a>  | 94.4%      |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">97</a>  | 94.2%      |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">77</a>  | 94.2%      |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">99</a>  | 94.%       |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">81</a>  | 94.%       |
| <a href="#">US 2013 0078234 A1</a> | ANTI B7-H3 ANTIBODY                                                                              | 28/03/13         | <a href="#">87</a>  | 93.2%      |
| <a href="#">WO 2012 147713 A1</a>  | ANTI-B7-H3 ANTIBODY                                                                              | 01/11/12         | <a href="#">89</a>  | 93.2%      |
| <a href="#">WO 2014 057687 A1</a>  | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14         | <a href="#">15</a>  | 93.2%      |
| <a href="#">WO 2014 061277 A1</a>  | ANTIBODY-DRUG CONJUGATE<br>PRODUCED BY BINDING THROUGH<br>LINKER HAVING HYDROPHILIC<br>STRUCTURE | 24/04/14         | <a href="#">15</a>  | 93.2%      |
| <a href="#">KR 20140033018 A</a>   | ANTI-B7-H3 ANTIBODY                                                                              | 17/03/14         | <a href="#">87</a>  | 93.2%      |
| <a href="#">CA 2885800 A1</a>      | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14         | <a href="#">10</a>  | 93.2%      |
| <a href="#">US 2013 0078234 A1</a> | ANTI B7-H3 ANTIBODY                                                                              | 28/03/13         | <a href="#">85</a>  | 93.2%      |
| <a href="#">WO 2012 147713 A1</a>  | ANTI-B7-H3 ANTIBODY                                                                              | 01/11/12         | <a href="#">88</a>  | 93.2%      |
| <a href="#">WO 2014 057687 A1</a>  | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14         | <a href="#">14</a>  | 93.2%      |
| <a href="#">WO 2014 061277 A1</a>  | ANTIBODY-DRUG CONJUGATE<br>PRODUCED BY BINDING THROUGH<br>LINKER HAVING HYDROPHILIC<br>STRUCTURE | 24/04/14         | <a href="#">14</a>  | 93.2%      |
| <a href="#">KR 20140033018 A</a>   | ANTI-B7-H3 ANTIBODY                                                                              | 17/03/14         | <a href="#">85</a>  | 93.2%      |
| <a href="#">CA 2885800 A1</a>      | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14         | <a href="#">9</a>   | 93.2%      |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">112</a> | 93.8%      |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">107</a> | 93.8%      |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">101</a> | 93.8%      |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">85</a>  | 93.8%      |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">108</a> | 93.8%      |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">99</a>  | 93.8%      |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">104</a> | 93.8%      |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">91</a>  | 93.8%      |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13         | <a href="#">110</a> | 93.8%      |

|                                    |                                                                                                  |          |                     |       |
|------------------------------------|--------------------------------------------------------------------------------------------------|----------|---------------------|-------|
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">103</a> | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">103</a> | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">89</a>  | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">102</a> | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">87</a>  | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">113</a> | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">109</a> | 93.8% |
| <a href="#">US 2013 0078234 A1</a> | ANTI B7-H3 ANTIBODY                                                                              | 28/03/13 | <a href="#">89</a>  | 92.8% |
| <a href="#">WO 2012 147713 A1</a>  | ANTI-B7-H3 ANTIBODY                                                                              | 01/11/12 | <a href="#">90</a>  | 92.8% |
| <a href="#">WO 2014 057687 A1</a>  | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14 | <a href="#">16</a>  | 92.8% |
| <a href="#">WO 2014 061277 A1</a>  | ANTIBODY-DRUG CONJUGATE<br>PRODUCED BY BINDING THROUGH<br>LINKER HAVING HYDROPHILIC<br>STRUCTURE | 24/04/14 | <a href="#">16</a>  | 92.8% |
| <a href="#">KR 20140033018 A</a>   | ANTI-B7-H3 ANTIBODY                                                                              | 17/03/14 | <a href="#">89</a>  | 92.8% |
| <a href="#">CA 2885800 A1</a>      | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14 | <a href="#">11</a>  | 92.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">106</a> | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">95</a>  | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">105</a> | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">93</a>  | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">109</a> | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">101</a> | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">111</a> | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">105</a> | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">107</a> | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">97</a>  | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">98</a>  | 93.8% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">79</a>  | 93.8% |
| <a href="#">US 2013 0078234 A1</a> | ANTI B7-H3 ANTIBODY                                                                              | 28/03/13 | <a href="#">91</a>  | 93.8% |
| <a href="#">WO 2012 147713 A1</a>  | ANTI-B7-H3 ANTIBODY                                                                              | 01/11/12 | <a href="#">91</a>  | 93.8% |
| <a href="#">WO 2014 057687 A1</a>  | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14 | <a href="#">17</a>  | 93.8% |
| <a href="#">WO 2014 061277 A1</a>  | ANTIBODY-DRUG CONJUGATE<br>PRODUCED BY BINDING THROUGH<br>LINKER HAVING HYDROPHILIC<br>STRUCTURE | 24/04/14 | <a href="#">17</a>  | 93.8% |
| <a href="#">KR 20140033018 A</a>   | ANTI-B7-H3 ANTIBODY                                                                              | 17/03/14 | <a href="#">91</a>  | 93.8% |
| <a href="#">CA 2885800 A1</a>      | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14 | <a href="#">12</a>  | 93.8% |
| <a href="#">WO 2013 154206 A1</a>  | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">100</a> | 93.6% |
| <a href="#">CA 2870126 A1</a>      | ANTI-FGFR2 ANTIBODY                                                                              | 17/10/13 | <a href="#">83</a>  | 93.6% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                          | 02/01/14 | <a href="#">34</a>  | 93.8% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                          | 03/05/12 | <a href="#">63</a>  | 93.8% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                                | 03/05/12 | <a href="#">34</a>  | 93.8% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                          | 02/01/14 | <a href="#">40</a>  | 93.2% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                          | 03/05/12 | <a href="#">66</a>  | 93.2% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                                | 03/05/12 | <a href="#">40</a>  | 93.2% |

|                                    |                                                                                         |          |                     |       |
|------------------------------------|-----------------------------------------------------------------------------------------|----------|---------------------|-------|
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                 | 02/01/14 | <a href="#">36</a>  | 92.8% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                 | 03/05/12 | <a href="#">64</a>  | 92.8% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                       | 03/05/12 | <a href="#">36</a>  | 92.8% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                 | 02/01/14 | <a href="#">42</a>  | 92.6% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                 | 03/05/12 | <a href="#">67</a>  | 92.6% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                       | 03/05/12 | <a href="#">42</a>  | 92.6% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                 | 02/01/14 | <a href="#">44</a>  | 92.6% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                 | 03/05/12 | <a href="#">68</a>  | 92.6% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                       | 03/05/12 | <a href="#">44</a>  | 92.6% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                 | 02/01/14 | <a href="#">50</a>  | 92.6% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                 | 03/05/12 | <a href="#">71</a>  | 92.6% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                       | 03/05/12 | <a href="#">50</a>  | 92.6% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                 | 02/01/14 | <a href="#">48</a>  | 92.6% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                 | 03/05/12 | <a href="#">70</a>  | 92.6% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                       | 03/05/12 | <a href="#">48</a>  | 92.6% |
| <a href="#">US 2014 0017253 A1</a> | RSPO3 Binding Agents and Uses Thereof                                                   | 16/01/14 | <a href="#">68</a>  | 93.6% |
| <a href="#">WO 2014 012007 A2</a>  | RSPO3 BINDING AGENTS AND USES THEREOF                                                   | 16/01/14 | <a href="#">68</a>  | 93.6% |
| <a href="#">CA 2878868 A1</a>      | RSPO3 BINDING AGENTS AND USES THEREOF                                                   | 16/01/14 | <a href="#">68</a>  | 93.6% |
| <a href="#">WO 2014 057687 A1</a>  | ANTIBODY-DRUG CONJUGATE                                                                 | 17/04/14 | <a href="#">29</a>  | 93.8% |
| <a href="#">WO 2014 061277 A1</a>  | ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE | 24/04/14 | <a href="#">29</a>  | 93.8% |
| <a href="#">CA 2885800 A1</a>      | ANTIBODY-DRUG CONJUGATE                                                                 | 17/04/14 | <a href="#">29</a>  | 93.8% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                 | 02/01/14 | <a href="#">46</a>  | 92.4% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                 | 03/05/12 | <a href="#">69</a>  | 92.4% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                       | 03/05/12 | <a href="#">46</a>  | 92.4% |
| <a href="#">US 2014 0140990 A1</a> | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF    | 22/05/14 | <a href="#">48</a>  | 94.6% |
| <a href="#">JP 2014515600 A</a>    |                                                                                         | 03/07/14 | <a href="#">54</a>  | 94.6% |
| <a href="#">KR 20140033014 A</a>   | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF    | 17/03/14 | <a href="#">48</a>  | 94.6% |
| <a href="#">CA 2857400 A1</a>      | METHOD FOR TREATING BREAST CANCER                                                       | 18/07/13 | <a href="#">204</a> | 94.6% |
| <a href="#">CA 2893376 A1</a>      | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGEMNTS THEREOF    | 04/10/12 | <a href="#">48</a>  | 94.6% |
| <a href="#">CA 2888908 A1</a>      | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF    | 04/10/12 | <a href="#">48</a>  | 94.6% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                 | 02/01/14 | <a href="#">70</a>  | 92.4% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                 | 03/05/12 | <a href="#">76</a>  | 92.4% |

|                                    |                                                                                                  |          |                    |       |
|------------------------------------|--------------------------------------------------------------------------------------------------|----------|--------------------|-------|
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                                | 03/05/12 | <a href="#">70</a> | 92.4% |
| <a href="#">US 2014 0004120 A1</a> | NOVEL ANTI-DR5 ANTIBODY                                                                          | 02/01/14 | <a href="#">38</a> | 92.1% |
| <a href="#">WO 2012 057288 A1</a>  | NOVEL ANTI-DR5 ANTIBODY                                                                          | 03/05/12 | <a href="#">65</a> | 92.1% |
| <a href="#">CA 2937979 A1</a>      | ANTI-DR5 ANTIBODY                                                                                | 03/05/12 | <a href="#">38</a> | 92.1% |
| <a href="#">WO 2014 057687 A1</a>  | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14 | <a href="#">31</a> | 92.9% |
| <a href="#">WO 2014 061277 A1</a>  | ANTIBODY-DRUG CONJUGATE<br>PRODUCED BY BINDING THROUGH<br>LINKER HAVING HYDROPHILIC<br>STRUCTURE | 24/04/14 | <a href="#">31</a> | 92.9% |
| <a href="#">CA 2885800 A1</a>      | ANTIBODY-DRUG CONJUGATE                                                                          | 17/04/14 | <a href="#">31</a> | 92.9% |
| <a href="#">US 2014 0140990 A1</a> | ANTIBODIES AGAINST KIDNEY<br>ASSOCIATED ANTIGEN 1 AND ANTIGEN<br>BINDING FRAGMENTS THEREOF       | 22/05/14 | <a href="#">49</a> | 94.2% |
| <a href="#">JP 2014515600 A</a>    |                                                                                                  | 03/07/14 | <a href="#">55</a> | 94.2% |
| <a href="#">KR 20140033014 A</a>   | ANTIBODIES AGAINST KIDNEY<br>ASSOCIATED ANTIGEN 1 AND ANTIGEN<br>BINDING FRAGMENTS THEREOF       | 17/03/14 | <a href="#">49</a> | 94.2% |